Steffen Jugl

474 total citations
21 papers, 357 citations indexed

About

Steffen Jugl is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Steffen Jugl has authored 21 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Rheumatology, 14 papers in Immunology and 9 papers in Hematology. Recurrent topics in Steffen Jugl's work include Spondyloarthritis Studies and Treatments (20 papers), Psoriasis: Treatment and Pathogenesis (14 papers) and Rheumatoid Arthritis Research and Therapies (10 papers). Steffen Jugl is often cited by papers focused on Spondyloarthritis Studies and Treatments (20 papers), Psoriasis: Treatment and Pathogenesis (14 papers) and Rheumatoid Arthritis Research and Therapies (10 papers). Steffen Jugl collaborates with scholars based in Switzerland, United Kingdom and United States. Steffen Jugl's co-authors include Kunal K. Gandhi, Philip J. Mease, Vibeke Strand, Peter Nash, Howard Thom, Iain B. McInnes, Luminita Pricop, Haijun Tian, Philip G. Conaghan and Shephard Mpofu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Lara D. Veeken and Arthritis Research & Therapy.

In The Last Decade

Steffen Jugl

21 papers receiving 355 citations

Peers

Steffen Jugl
Tamara Rusman Netherlands
Helena Raffayová Slovakia
Michael Rissler Switzerland
D Halter United States
Maria Stefania Cutro Italy
J Brückel United States
I. Spiller Germany
Lorna Cawkwell United Kingdom
Damiano Currado Italy
M. van Lunteren Netherlands
Tamara Rusman Netherlands
Steffen Jugl
Citations per year, relative to Steffen Jugl Steffen Jugl (= 1×) peers Tamara Rusman

Countries citing papers authored by Steffen Jugl

Since Specialization
Citations

This map shows the geographic impact of Steffen Jugl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steffen Jugl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steffen Jugl more than expected).

Fields of papers citing papers by Steffen Jugl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steffen Jugl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steffen Jugl. The network helps show where Steffen Jugl may publish in the future.

Co-authorship network of co-authors of Steffen Jugl

This figure shows the co-authorship network connecting the top 25 collaborators of Steffen Jugl. A scholar is included among the top collaborators of Steffen Jugl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steffen Jugl. Steffen Jugl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strand, Vibeke, Atul Deodhar, Rieke Alten, et al.. (2021). Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors: Multinational Real-World Findings.. PubMed. 27(8). e446–e455. 12 indexed citations
2.
Conaghan, Philip G., Rieke Alten, Atul Deodhar, et al.. (2020). Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. RMD Open. 6(2). e001240–e001240. 30 indexed citations
3.
Strand, Vibeke, Atul Deodhar, Rieke Alten, et al.. (2020). Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors. JCR Journal of Clinical Rheumatology. 27(8). e446–e455. 19 indexed citations
4.
Coates, Laura C., Peter Nash, Tore K Kvien, et al.. (2020). Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. Seminars in Arthritis and Rheumatism. 50(4). 709–718. 22 indexed citations
5.
Mease, Philip J., Ernest Choy, Peter Nash, et al.. (2019). Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. SHILAP Revista de lepidopterología. 6(3). 113–121. 4 indexed citations
6.
Strand, Vibeke, Iain B. McInnes, Philip J. Mease, et al.. (2019). Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. Journal of Comparative Effectiveness Research. 8(7). 497–510. 18 indexed citations
7.
Deodhar, Atul, Philip G. Conaghan, Tore K Kvien, et al.. (2019). Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.. PubMed. 37(2). 260–269. 19 indexed citations
8.
9.
Colombo, Giorgio Lorenzo, et al.. (2018). Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. ClinicoEconomics and Outcomes Research. Volume 10. 477–491. 6 indexed citations
10.
Sullivan, William G., et al.. (2018). Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK. PharmacoEconomics. 36(7). 867–878. 7 indexed citations
11.
McInnes, Iain B., Philip J. Mease, Georg Schett, et al.. (2018). Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Research & Therapy. 20(1). 113–113. 22 indexed citations
12.
Emery, Paul, et al.. (2018). Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. PharmacoEconomics. 36(8). 1015–1027. 17 indexed citations
13.
Maksymowych, Walter P., Vibeke Strand, Peter Nash, et al.. (2018). Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. European Journal of Rheumatology. 5(4). 216–223. 12 indexed citations
14.
Goeree, Ron, et al.. (2018). Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. Journal of Medical Economics. 22(1). 45–52. 11 indexed citations
15.
Nash, Peter, Iain B. McInnes, Philip J. Mease, et al.. (2018). Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. Rheumatology and Therapy. 5(1). 99–122. 37 indexed citations
16.
17.
McInnes, Iain B., Peter Nash, Christopher T. Ritchlin, et al.. (2018). Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. Journal of Comparative Effectiveness Research. 7(11). 1107–1123. 31 indexed citations
18.
Krüger, Klaus, U. von Hinüber, Florian Meier, et al.. (2018). Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatology International. 38(11). 2121–2131. 33 indexed citations
19.
Marzo‐Ortega, Helena, et al.. (2017). 108. THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS TUMOUR NECROSIS FACTOR α INHIBITOR BIOSIMILARS FOR ANKYLOSING SPONDYLITIS IN THE UK. Lara D. Veeken. 56(suppl_2). 3 indexed citations
20.
Goeree, Ron, et al.. (2017). Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. Journal of Medical Economics. 21(2). 163–173. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamara Rusman Breakdown of academic impact, for papers by Helena Raffayová Breakdown of academic impact, for papers by Michael Rissler Breakdown of academic impact, for papers by D Halter Breakdown of academic impact, for papers by Maria Stefania Cutro Breakdown of academic impact, for papers by J Brückel Breakdown of academic impact, for papers by I. Spiller Breakdown of academic impact, for papers by Lorna Cawkwell Breakdown of academic impact, for papers by Damiano Currado Breakdown of academic impact, for papers by M. van Lunteren
Rankless by CCL
2026